Redeye comments on the preliminary one-year results from the ProTrans-Young trial, announced by NextCell yesterday after market close ahead of the company’s presentation at the IDF World Diabetes Congress. While the available data is limited and difficult to interpret, making it too early to draw firm conclusions, the outcome is not what the market was hoping for.
LÄS MER
